In category: Idiopathic Pulmonary Fibrosis (IPF)

We are testing an investigational medicine called orvepitant as a treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF), a condition that causes scarring of the lungs. An investigational medicine does not yet have a license to be marketed or sold. It is still being tested to see if it works and to make […]

Primary Objective: To determine what is the clinical and cost effectiveness of ambulatory oxygen therapy (AOT) in patients with idiopathic pulmonary fibrosis (IPF) Inclusion Criteria: Clinically diagnosed IPF, confirmed by an ILD MDT linked to an NHS specialist commissioned IPF service Breathlessness with MRC dyspnoea score ≥2 Click here to Read a Summary of this […]

Orphan drugs are medicines for diagnosis, prevention or treatment of life-threatening or progressive disorders that are rare (affecting less than 1 in 2,000 people). An example is Idiopathic Pulmonary Fibrosis (IPF). We are approaching a number of people who have Idiopathic Pulmonary Fibrosis (IPF) to learn more about how and why they have or have […]

Fibrotic lung conditions result in scarring of the lung tissue. This causes shortness of breath and cough, and has an enormous impact on people’s quality of life. We currently know that progressive lung scarring may be caused by a few conditions like Rheumatoid Arthritis and previous exposure to asbestos, birds (pigeons, parrots and budgies particularly) […]

Idiopathic Pulmonary Fibrosis is a disease which results in damage to the lung tissue. It is characterised by progressive loss of lung function (measured by breathing tests) and increasing breathlessness. It is incurable and there are few available treatments. It is thought to occur because of tiny “scars” (which we call fibrosis) that develop throughout […]